Home page  |  About this library  |  Help  |  Clear       English  |  French  |  Spanish  
Expand Document
Expand Chapter
Full TOC
Preferences
to previous section to next section

close this bookGuidelines for the Treatment of Malaria (WHO; 2006; 266 pages) View the PDF document
View the documentGlossary
View the documentAbbreviations
open this folder and view contents1. Introduction
View the document2. The clinical disease
open this folder and view contents3. Treatment objectives
open this folder and view contents4. Diagnosis of malaria
open this folder and view contents5. Resistance to antimalarial medicines9
open this folder and view contents6. Antimalarial treatment policy
close this folder7. Treatment of uncomplicated P. Falciparum malaria10
View the document7.1 Assessment
View the document7.2 Antimalarial combination therapy
View the document7.3 The choice of artemisinin-based combination therapy options
View the document7.4 Practical aspects of treatment with recommended ACTs
View the document7.5 Incorrect approaches to treatment
View the document7.6 Additional aspects of clinical management
View the document7.7 Operational issues in treatment management
View the document7.8 Management of treatment failures
View the document7.9 Treatment in specific populations and situations
View the document7.10 Coexisting morbidities
open this folder and view contents8. Treatment of severe falciparum malaria14
open this folder and view contents9. Treatment of malaria caused by P. vivax, P. ovale or P. malariae19
View the document10. Mixed malaria infections
open this folder and view contents11. Complex emergencies and epidemics
open this folder and view contentsAnnexes
 

7.8 Management of treatment failures

7.8.1 Failure within 14 days

Treatment failure within 14 days of receiving an ACT is very unusual. Of 39 trials of artemisinin or its derivatives, which together enrolled 6124 patients, 32 trials (4917 patients) had no failures at all by day 14. In the remaining 7 trials, failure rates at day 14 ranged from 1% to 7%. The majority of treatment failures occur after 2 weeks of initial treatment. In many cases failures are missed because patients presenting with malaria are not asked whether they have received antimalarial treatment within the preceding 1-2 months. Recurrence of falciparum malaria can be the result of a reinfection, or a recrudescence (i.e. failure). In an individual patient it may not be possible to distinguish recrudescence from reinfection, although if fever and parasitaemia fail to resolve or recur within 2 weeks of treatment then this is considered a failure of treatment. Wherever possible treatment failure must be confirmed parasitologically - preferably by blood slide examination (as HRP2-based tests may remain positive for weeks after the initial infection even without recrudescence). This may require transferring the patient to a facility with microscopy; transfer may be necessary anyway to obtain second-line treatment. Treatment failures may result from drug resistance, poor adherence or unusual pharmacokinetic properties in that individual. It is important to determine from the patient's history whether he or she vomited previous treatment or did not complete a full course. Treatment failures within 14 days should be treated with a second-line antimalarial (see section 7.8.3).

7.8.2 Failure after 14 days

Recurrence of fever and parasitaemia more than 2 weeks after treatment, which could result either from recrudescence or new infection, can be retreated with the first-line ACT. Parasitological confirmation is desirable but not a precondition. If it is a recrudescence, then the first-line treatment should still be effective in most cases. This simplifies operational management and drug deployment. However, reuse of mefloquine within 28 days of first treatment is associated with an increased risk of neuropsychiatric sequelae and, in this particular case, second-line treatment should be given. If there is a further recurrence, then malaria should be confirmed parasitologically and second-line treatment given.

7.8.3 Recommended second-line antimalarial treatments

On the basis of the evidence from current practice and the consensus opinion of the Guidelines Development Group, the following second-line treatments are recommended, in order of preference:

• alternative ACT known to be effective in the region,
• artesunate + tetracycline or doxycycline or clindamycin,
• quinine + tetracycline or doxycycline or clindamycin.


The alternative ACT has the advantages of simplicity, and where available, co-formulation to improve adherence. The 7-day quinine regimes are not well tolerated and adherence is likely to be poor if treatment is not observed.

Summary of recommendations on second-line antimalarial treatment for uncomplicated falciparum malaria

RECOMMENDATIONS

LEVEL OF EVIDENCE

Alternative ACT known to be effective in the region.

O

Artesunate (2 mg/kg bw once a day) + tetracycline (4 mg/kg bw four times a day) or doxycycline (3.5 mg/kg bw once a day) or clindamycin (10 mg/kg bw twice a day). Any of these combinations to be given for 7 days.

O

Quinine (10 mg salt/kg bw three times a day) + tetracycline or doxycycline or clindamycin. Any of these combinations to be given for 7 days.

O

to previous section to next section

Please provide your feedback   English  |  French  |  Spanish